Last reviewed · How we verify

NCT06006897

Pain, Physical Activity, Posture and Quality of Life in Post-COVID-19 Individuals With Idiopathic Scoliosis

Completed Last updated 25 May 2025
What this trial tests

trial testing Physical Evaluations of post-COVID-19 individuals in COVID-19 Respiratory Infection in 41 participants. Completed in 30 December 2024.

Timeline
16 June 2023
Primary endpoint
30 September 2024
30 December 2024

Quick facts

Lead sponsorIzmir Democracy University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment41
Start date16 June 2023
Primary completion30 September 2024
Estimated completion30 December 2024
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Izmir Democracy University

Who can join

18 and older, any sex, with COVID-19 Respiratory Infection or Idiopathic Scoliosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is not known to what extent the COVID-19 virus affects individuals with scoliosis during the prolonged COVID-19 pandemic. Therefore, in this study it was aimed to comparatively investigate pain severity, posture disorders that can be assessed by artificial intelligence, physical activity levels and quality of life in individuals with idiopathic scoliosis with and without COVID-19.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Physical Evaluations of post-COVID-19 individuals

Trials testing the same drug.

Other recruiting trials for COVID-19 Respiratory Infection

Currently open trials in the same condition.

Other Izmir Democracy University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06006897.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing